Arcus Biosciences Inc. (RCUS) Price Targets: What Do They Mean?


As of Friday close, Arcus Biosciences Inc.’s (NYSE:RCUS) stock was down -$0.51, moving down -3.01 percent to $16.45. The average number of shares traded per day over the past five days has been 1,830,140 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.10 fall in that time frame. In the last twenty days, the average volume was 1,225,470, while in the previous 50 days, it was 1,143,536.

Since last month, RCUS stock retreated -16.28%. Shares of the company fell to $15.70 on 03/10/23, the lowest level in the past month. A 52-week high of $39.75 was reached on 01/27/23 after having rallying from a 52-week low of $15.70. Since the beginning of this year, RCUS’s stock price has dropped by -20.45% or -$4.23, and marked a new high 7 times. However, the stock has declined by -58.62% since its 52-week high.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


RCUS stock investors should be aware that Arcus Biosciences Inc. (RCUS) stock had its last reported insider trading activity 50 days ago on Jan 27. Jarrett Jennifer, the Chief Operating Officer of the company, disposed of 1,600 shares for $23.52 on Jan 27. It resulted in a $37,632 divestment by the insider. Jarrett Jennifer sold 300 shares at an average price of $23.56 on Jan 26. The insider now owns 416,546 shares following the transaction. On Dec 16, Chief Operating Officer Jarrett Jennifer sold 16,482 shares at $30.75 apiece. The transaction was valued at $506,822.

Valuation Metrics

The stock’s beta is 0.89. Besides these, the trailing price-to-sales (P/S) ratio of 10.74, the price-to-book (PB) ratio of 1.82, and the price-to-cash flow ratio of 2.79 may also be considered.

Financial Health

In the three months ended September 29, Arcus Biosciences Inc.’s quick ratio stood at 5.50, while its current ratio was 5.50, showing that the company is able to pay off its debt. Based on annual data, RCUS earned $392.0 million in gross profit and brought in $112.0 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -42.80%. Return on equity (ROE) for the past 12 months was -36.80%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. RCUS’s revenue fell -953.18% to $33.58 million during the quarter, while net income inched up to $33.66 million. While analysts expected Arcus Biosciences Inc. to report -$1.04 quarterly earnings, the actual figure was -$0.9 per share, beating the consensus estimate by 13.50%. During the quarter, the company generated -$74.97 million in EBITDA. The liabilities of Arcus Biosciences Inc. were 688.0 million at the end of its most recent quarter ended September 29, and its total debt was $119.19 million. The value of shareholders’ equity is $73.01 million.

Technical Picture

This quick technical analysis looks at Arcus Biosciences Inc.’s (RCUS) price momentum. With a historical volatility rate of 42.81%, the RSI 9-day stood at 30.14% on 17 March.

With respect to its five-day moving average, the current Arcus Biosciences Inc. price is down by -0.60% percent or -$0.10. At present, RCUS shares trade -14.77% below its 20-day simple moving average and -42.40% percent below its 100-day simple moving average. However, the stock is currently trading approximately -19.32% below its SMA50 and -13.19% below its SMA200.

Stochastic coefficient K was 34.28% and Stochastic coefficient D was 38.32%, while ATR was 0.89. Given the Stochastic reading of 23.58% for the 14-day period, the RSI (14) reading has been calculated as 33.33%. As of today, the MACD Oscillator reading stands at -0.24, while the 14-day reading stands at -0.53.


Please enter your comment!
Please enter your name here